Lunai Bioworks (LNAI) Cash & Equivalents (2011 - 2026)

Lunai Bioworks' Cash & Equivalents history runs 16 years deep, the most recent figure standing at $3.2 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 241.85% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $3.2 million (up 241.85% YoY), while the FY2025 annual figure was $92700.0, down 57.95% from the prior year.
• Cash & Equivalents was $3.2 million for Q1 2026 at Lunai Bioworks, up from $491645.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $11.2 million in Q1 2022 to a low of $92700.0 in Q2 2025.
• Historically, Cash & Equivalents has averaged $2.6 million across 5 years, with a median of $624808.0 in 2025.
• The sharpest annual moves came in 2023 and 2026: Cash & Equivalents sank 94.08% in 2023, then jumped 241.85% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $4.1 million in 2022, then tumbled by 94.08% to $243980.0 in 2023, then climbed by 27.78% to $311764.0 in 2024, then jumped by 57.7% to $491645.0 in 2025, then jumped by 541.78% to $3.2 million in 2026.
• The last three Cash & Equivalents figures came in at $3.2 million (Q1 2026), $491645.0 (Q4 2025), and $624808.0 (Q3 2025), per Business Quant data.